| Recruitment status | Suspended |
| Unique ID issued by UMIN | UMIN000027279 |
| Receipt No. | R000031257 |
| Scientific Title | Open-labeled, non-randomized, single institute study to evaluate safety and efficacy of dendritic cell vaccination using artificial antigens or tumor lysate for patients with advanced malignancies. |
| Date of disclosure of the study information | 2017/05/09 |
| Last modified on | 2020/12/17 (Ver. 4) |
| Basic information | ||
| Public title | Open-labeled, non-randomized, single institute study to evaluate safety and efficacy of dendritic cell vaccination using artificial antigens or tumor lysate for patients with advanced malignancies. | |
| Acronym | Dendritic cell vaccination for patients with advanced malignancies | |
| Scientific Title | Open-labeled, non-randomized, single institute study to evaluate safety and efficacy of dendritic cell vaccination using artificial antigens or tumor lysate for patients with advanced malignancies. | |
| Scientific Title:Acronym | Dendritic cell vaccination for patients with advanced malignancies | |
| Region |
|
|
| Condition | |||||||
| Condition | Patients with advanced malignancies | ||||||
| Classification by specialty |
|
||||||
| Classification by malignancy | Malignancy | ||||||
| Genomic information | YES | ||||||
| Objectives | |
| Narrative objectives1 | The aim of this study is to investigate safety and efficacy of dendritic cell vaccination using artificial antigens or tumor lysate for patients with refractory or relapsed advanced malignancies. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | Adverse events and Efficacy |
| Key secondary outcomes | Immunological response,Progression free survival, Overall survival |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Patients are injected intradermally at axilla or inguinal region with dendritic cells pulsed with artificial antigens or tumor lysate (approximately 1x107). At the same time, OK432 (0.5-3KE) is injected subcutaneously in the vicinity of dendritic-cell-injected site. Injection of dendritic cells is performed every two weeks seven times. WT1 peptide (HLA-A*2402-restricted, modified p235-243 peptide or HLA-A*0201-restricted p126-134 peptide) and MUC1 peptide are employed for artificial antigens. Safety and efficacy are evaluated after seventh DC vaccination. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with advanced or relapsed malignancies
2. Having evaluable disease by RECIST criteria 3. Performance Status; 0-2 4. Survival period is expected more than 4 months 5. Meet the following criteria for organ functions 1) WBC more than 2,500/microliter, Hemoglobin more than 9.0 g/dl, Platelet more than 90,000/microliter 2) Serum AST/ALT less than 2.5 folds of the upper normal limit 3) Serum bilirubin less than1.5 folds of the upper normal limit 4) Serum Albumin more than 3.0g/dl 5) Serum creatinine within normal limitation 6. Patients can tolerate blood component collection (apheresis) to collect peripheral blood mononuclear cells. 7. HLA-A*2402, 0201 or 0206 positive (WT1 DC) 8. Informed consent has been obtained. |
|||
| Key exclusion criteria | 1. There is deep-seated active infection.
2. There are severe complications including malignant hypertension, cardiac failure, liver cirrhosis, severe DM, severe lung disease, active interstitial pneumonitis. 3. Patients who have complications are considered inappropriate for the trial. 4. There are other malignancies. 5. Pregnant or lactating woman. 6. Past history of severe drug allergy. 7. There is severe psychiatric disease. 8. The patient is considered inappropriate for the trial by a responsible doctor. |
|||
| Target sample size | 200 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Sapporo Hokuyu Hospital | ||||||
| Division name | Dept. of Internal Medicine | ||||||
| Zip code | 003-0006 | ||||||
| Address | 6-6-5-1 Higashisapporo Shiroishiku Sapporo | ||||||
| TEL | 011-865-0111 | ||||||
| ogasawara@hokuyu-aoth.org | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Sapporo Hokuyu Hospital | ||||||
| Division name | Cellular Immunotherapy Center | ||||||
| Zip code | 003-0006 | ||||||
| Address | 6-6-5-1 Higashisapporo Shiroishiku Sapporo | ||||||
| TEL | 011-865-0111 | ||||||
| Homepage URL | |||||||
| i.yamada0414@hokuyu-aoth.org | |||||||
| Sponsor | |
| Institute | Sapporo Hokuyu Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Sapporo Hokuyu Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Sapporo Hokuyu Hostital IRB |
| Address | 6-6-5-1 Higashisapporo Shiroishiku Sapporo. JAPAN |
| Tel | 011-865-0111 |
| shiori-t@hokuyu-aoth.org | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Suspended | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000031257 |